Irfan Munir
Nephrology · Fort Wayne, INNPI 1073515086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 269 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$844
- Akebia Therapeutics Inc$578
- Bayer$466
- Otsuka America Pharmaceutical, Inc.$369
- Vifor Pharma, Inc.$367
- Fresenius USA Marketing, Inc.$326
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,02897%
- Education$1473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $844 |
| Akebia Therapeutics Inc | 38 | $578 |
| Bayer | 39 | $466 |
| Otsuka America Pharmaceutical, Inc. | 17 | $369 |
| Vifor Pharma, Inc. | 18 | $367 |
| Fresenius USA Marketing, Inc. | 18 | $326 |
| Amgen(2 entities) | 17 | $263 |
| Travere Therapeutics, Inc. | 8 | $232 |
| OPKO Pharmaceuticals, LLC | 11 | $196 |
| Calliditas Therapeutics US Inc. | 7 | $161 |
| Mallinckrodt Enterprises LLC | 3 | $156 |
| Novartis | 7 | $140 |
| GSK | 3 | $132 |
| Boehringer Ingelheim | 7 | $112 |
| Bard Peripheral Vascular, Inc. | 1 | $101 |
| Mallinckrodt Hospital Products Inc. | 5 | $100 |
| Aurinia Pharma U.S., Inc. | 5 | $95 |
| Ardelyx, Inc. | 5 | $84 |
| Nxstage Medical, Inc. | 1 | $72 |
| Novo Nordisk | 3 | $69 |
| Baxter Healthcare | 1 | $55 |
| Cormedix Inc. | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Vertex | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $15 |
| Shire North American Group Inc | 1 | $11 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,175 in reported general payments places this provider in the 80th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 375 | $323,134 |
| JardianceEmpagliflozin | 226 | $183,261 |
| VelphoroSucroferric Oxyhydroxide | 28 | $121,792 |
| MounjaroTirzepatide | 80 | $90,505 |
| AuryxiaFerric Citrate | 18 | $40,652 |
| OzempicSemaglutide | 24 | $25,680 |
| KerendiaFinerenone | 22 | $24,090 |
| EliquisApixaban | 19 | $18,337 |
| Lanthanum Carbonate | 14 | $13,586 |
| Sevelamer Carbonate | 80 | $10,135 |
| DapagliflozinDapagliflozin Propanediol | 19 | $8,934 |
| Cinacalcet Hcl | 32 | $5,400 |
| Clonidine | 24 | $3,431 |
| Losartan Potassium | 286 | $2,296 |
| Bumetanide | 60 | $2,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $844 | $323,134375 claims |
| Boehringer IngelheimJardiance | $112 | $183,261226 claims |
| Fresenius USA Marketing, Inc.Velphoro | $326 | $121,79228 claims |
| Akebia Therapeutics IncAuryxia | $578 | $40,65218 claims |
| Novo NordiskOzempic | $69 | $25,68024 claims |
| BayerKerendia | $466 | $24,09022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 238 nephrology providers in Indiana.
Other nephrology in Fort Wayne
- Andrew OshaughnessyFort Wayne$64K
- John DuckerFort Wayne$8K
- Melanie BarridoFort Wayne$6K
- Sajjad HabibFort Wayne$4K
- Kanakapura VenkatakrishnaFort Wayne$4K
- Kiran Mandya ChikkalingaiahFort Wayne$4K
- Prasanna IsaacFort Wayne$3K
- Garima GuptaFort Wayne$3K
- Guy AsherFort Wayne$3K
- Rajiv AgarwalIndianapolis$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.